EGFR and lung adenocarcinoma: However, even with EGFR-TKI use almost a quarter of the patients experienced SREs in this study, and in other studies, the reported frequency of SREs is even higher (37.3% to 58%) in patients with EGFR-mutated lung adenocarcinoma mainly treated with EGFR-TKIs [12,49,54,55,56,57].